Novartis hits record profits near $6B

Novartis achieved record profits and exceeded expectations by approximately $6 billion in the second quarter of the year, while maintaining its forecasts for 2026, despite the expiration of patent protection for several of its key medicines. Basic operating profits rose to $5.94 billion, and the company's outlook depends on results from important clinical trials expected to generate annual sales of up to $10 billion. The company faces pressure following the expiration of patents on some drugs, especially "Entresto," but it aims to strengthen its internal production lines and focus on research and development of new medications, continuing to bolster its investments despite market and competitive challenges.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل